饶毅回应：我为何向刘革新开炮

Core Viewpoint - The controversy surrounding the promotion of ergothioneine by Kelun Pharmaceutical and the criticism from renowned biologist Rao Yi highlights the ongoing debate about the legitimacy and marketing practices of health supplements in the pharmaceutical industry [1][2][3]. Group 1: Criticism of Ergothioneine - Rao Yi labeled ergothioneine as a "fake drug" due to the lack of sufficient evidence for its approval as a legitimate medication, suggesting that it is being marketed as a health supplement to deceive consumers [2][3]. - Rao Yi criticized the marketing tactics employed by Kelun's chairman, Liu Gexin, who showcased his physique in advertisements for ergothioneine, arguing that such methods mislead the public into believing that the supplement can deliver similar results [7][8]. Group 2: Kelun Pharmaceutical's Response - Kelun Pharmaceutical responded to Rao Yi's allegations by emphasizing the scientific basis and safety certifications of ergothioneine, asserting that it has been validated through clinical research in various health domains [4][6]. - The company highlighted that ergothioneine is recognized as a novel dietary supplement in developed regions, countering Rao Yi's claims by stating that the lack of drug approval does not invalidate the efficacy of dietary supplements [4][6]. Group 3: Broader Implications for the Industry - The exchange between Rao Yi and Kelun Pharmaceutical reflects a larger issue within the health supplement industry, where the distinction between legitimate products and those lacking scientific backing is often blurred [3][6]. - Rao Yi's history of criticizing other pharmaceutical products indicates a pattern of scrutiny towards the marketing practices of health supplements, raising questions about consumer protection and regulatory standards in the industry [4][6].